Page last updated: 2024-12-11
2-propyl-2,4-pentadienoic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2-propyl-2,4-pentadienoic acid: toxic metabolite of valproic acid; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6441809 |
| CHEMBL ID | 3706507 |
| CHEBI ID | 80642 |
| SCHEMBL ID | 1003653 |
| MeSH ID | M0190230 |
Synonyms (16)
| Synonym |
|---|
| 72010-18-5 |
| 2-propyl-2,4-pentadienoic acid |
| 2,4-diene-vpa |
| (e,z)-2-propyl-2,4-pentadienoic acid |
| (2e)-2-propylpenta-2,4-dienoic acid |
| 2-ppda |
| 2,4-pentadienoic acid, 2-propyl- |
| (e,z) 2-propyl-2,4-pentadienoic acid |
| SCHEMBL1003653 |
| (e,z)2-propyl-2,4-pentadienoic acid |
| CHEBI:80642 |
| CHEMBL3706507 |
| (e)-2-propyl-2,4-pentadienoic acid |
| Q27149692 |
| 2-propylpenta-2,4-dienoic acid |
| STARBLD0002427 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Our results indicate that all three risk factors clearly increase the metabolic conversion of VPA to 4-en, the most toxic VPA metabolite, and that polytherapy and high VPA serum level result in the inhibited beta-oxidative metabolism of VPA to 2-en." | ( Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. Fukushima, Y; Hirano, T; Ishida, M; Kaneko, S; Koide, N; Kondo, T; Muranaka, H; Otani, K; Yokoyama, M, ) | 0.13 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Rats were dosed ip with 100 mg/kg of VPA, 4-ene-, or 2,4-diene-VPA, and methylated bile and urine extracts were analyzed by LC/MS/MS and GC/MS, respectively." | ( Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Abbott, F; Farrell, K; Kassahun, K, ) | 0.35 |
| " Bile samples collected from male Sprague-Dawley rats dosed ip with (E)-2,4-diene VPA (100 mg/kg) were analyzed by LC/MS/MS." | ( Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation. LC/MS/MS characterization of the GSH-glucuronide diconjugates. Abbott, FS; Tang, W, 1996) | 0.54 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| methyl-branched fatty acid | Any branched-chain fatty acid containing methyl branches only. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Pathways (2)
| Pathway | Proteins | Compounds |
|---|---|---|
| Valproic Acid Metabolism Pathway | 11 | 32 |
| Valproic acid pathway | 0 | 22 |
Research
Studies (2)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||